نتایج جستجو برای: clindamycin phosphate

تعداد نتایج: 107659  

Journal: :Emerging Infectious Diseases 2007

Journal: :British Dental Journal 2005

2012
Ahmad Alikhani Ebrahim Salehifar

Clindamycin is a lincosamide antibiotic which is approved for the treatment of Anaerobic, Streptococcal and Staphylococcal infections. There has been an increased interest in the use of clindamycin since it achieves high intracellular levels in phagocytic cells, high levels in bone and appears to have an antitoxin effect against the toxin elaborating strains of streptococci and staphylococci. C...

Journal: :Journal of clinical microbiology 2008
Claire Daurel Corinne Huet Anne Dhalluin Michèle Bes Jerome Etienne Roland Leclercq

In staphylococci, inducible macrolide-lincosamide-streptogramin B (MLS(B)) resistance is conferred by the erm(C) or erm(A) gene. This phenotype is characterized by the erythromycin-clindamycin "D-zone" test. Although clindamycin appears active in vitro, exposure of MLS(B)-inducible Staphylococcus aureus to this antibiotic may result in the selection of clindamycin-resistant mutants, either in v...

Journal: :Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2005
Michael Ramharter Sunny Oyakhirome Peter Klein Klouwenberg Ayola A Adégnika Sélidji T Agnandji Michel A Missinou Pierre-Blaise Matsiégui Benjamin Mordmüller Steffen Borrmann Jürgen F Kun Bertrand Lell Sanjeev Krishna Wolfgang Graninger Saadou Issifou Peter G Kremsner

BACKGROUND Artemisinin-based drug combinations are the mainstay in the fight against drug-resistant malaria in Africa. Currently available antimalarial drug combinations that include artemisinins are pharmacokinetically unmatched and are therefore potentially increasing the risk of selection of resistant mutants in areas in which the rate of transmission of malaria is high. We tested the potent...

2012
N Seifi N Kahani E Askari S Mahdipour Nasab M Naderi

BACKGROUND AND OBJECTIVES Staphylococcus aureus is an important agent in hospital and community-associated infections, causing high morbidity and mortality. Introduction of the new antimicrobial classes for this pathogen has been usually followed by the emergence of resistant strains through multiple mechanisms. For instance, resistance to clindamycin (CLI)can be constitutive or inducible. Indu...

Journal: :The Journal of antimicrobial chemotherapy 2001
M Fines M Gueudin A Ramon R Leclercq

A clinical isolate of Streptococcus pyogenes UCN1 intermediate to erythromycin (MIC 1 mg/L) and susceptible to clindamycin (MIC 0.03 mg/L) harboured an inducible erm(TR) gene encoding a ribosomal methylase. We have selected in vitro, in the presence of concentrations of clindamycin ranging from 0.12 to 1 mg/L, one-step mutants that are highly resistant to this antibiotic (MIC 64 mg/L) at a freq...

Clindamycin is a lincosamide antibiotic which is approved for the treatment of anaerobic, streptococcal and staphylococcal infections. There has been an increased interest in the use of clindamycin since it achieves high intracellular levels in phagocytic cells, high levels in bone and appears to have an antitoxin effect against the toxin elaborating strains of streptococci and staphylococci. C...

Journal: :Journal of clinical microbiology 2004
M Desjardins K L Delgaty K Ramotar C Seetaram B Toye

Increased rates of erythromycin resistance among group B Streptococcus (GBS) and group A Streptococcus (GAS) have been reported. Cross-resistance to clindamycin may be present, depending on the mechanism of resistance. We determined the prevalence of macrolide-resistant determinants in GBS and GAS isolates to guide the laboratory reporting of erythromycin and clindamycin susceptibility. Suscept...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید